License CRG Technologies

Explore our Technology Portfolio

If you are exploring licensing opportunities at the CRG, the TBDO can guide you to a wide range of suitable researchers and their technologies.

Search Results - Drug+Targets+%26+Mechanisms

3 Results Sort By:
New, targeted lung cancer treatment with splicing-modifying antisense oligonucleotides
A lead splicing-modifying antisense oligonucleotide (AON) locally delivered to the lungs of different mice models of lung cancer effectively reduces tumor growth in vivo. The lead AON could be applicable to the targeted treatment of lung adenocarcinoma, lung squamous cell carcinoma, breast, liver, prostate, colon, cervix and other tumor types displaying...
Published: 1/28/2019   |   Inventor(s): Juan Valcarcel, Jordi Hernandez Ribera, Elias Bechara
Keywords(s): Oncology, RNA Modulation Technologies, Spliceosome / Splicing
Category(s): Biotechnology, Drug Targets & Mechanisms, Therapeutics (Biologics & Compounds)
A unique B-cell model system for transdifferentiation and human immune modulation
The cells, derived from a B-cell acute lymphoblastic leukemia cell line, can be easily converted into human macrophage-like cells with 100% efficiency in just few days, recapitulating human macrophage function and biology better and more conveniently than existing model systems. They can be used for basic research and drug development purposes in relation...
Published: 2/19/2019   |   Inventor(s): Thomas Graf, Francesca Rapino
Keywords(s): Autoimmune Diseases, Cardiovascular Diseases, Cell-based Assay, Immune / Inflammatory Diseases, Immuno-oncology, Infectious Diseases, Metabolic Diseases, Neurodegenerative Diseases, Oncology
Category(s): Therapeutics (Biologics & Compounds), Research Tools (cell lines, mice, kits, ABs, ...), Drug Targets & Mechanisms
Novel strategy to find and eliminate latent HIV
The technology maps insert-specific expression across thousands of integrated HIV proviruses in the whole human genome.The technology can be used to identify the best (mix of) latency-reversing agents that can reactivate all latent HIV viruses which escape from antiretroviral therapies, making them susceptible to destruction.Technology:After integration...
Published: 2/19/2019   |   Inventor(s): Guillaume Filion, Heng_chang Chen
Keywords(s): Cell-based Assay, Gene Regulation, Infectious Diseases
Category(s): Therapeutics (Biologics & Compounds), Drug Targets & Mechanisms, Methodology

 

 

Categories

Featured Technologies

Most Popular Keywords

Latest Technologies Published

Search our database for an up-to-date listing of CRG intellectual property available for licensing